- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07774845
Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis
Development and Validation of a New Method to Valuate the Platelet-Plasma Lipid Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis
The objective of this clinical trial is to compare the effect of two different lipid emulsion formulations versus no emulsion on platelet aggregation in individuals without a history of ischemic disease. The hypothesis of this study is:
Platelet aggregation is inversely associated with higher plasma lipid concentrations.
The researchers will compare platelet aggregation in the presence and absence of lipid nanoemulsions in vitro through three pathways using the agonists collagen, adenosine diphosphate, and arachidonic acid. The tests will be performed using light-transmission aggregometry. Various participant parameters, such as lipid profile, will be evaluated to analyze possible correlations with the observed results.
Participants must:
Meet the study's inclusion criteria; Sign the informed consent form; Report to the blood draw laboratory at InCor's AB on the scheduled date and time after fasting for at least 8 hours.
Study Overview
Status
Conditions
Detailed Description
A prospective case-control study in which the selected volunteers will serve as their own controls.
Participant Selection:
Volunteers with no known atherosclerotic disease will be selected from among employees of InCor/HCFMUSP and, if necessary, from the donor waiting list of the HCFMUSP blood bank.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: José C Nicolau, Senior Professor
- Phone Number: 11971514117
- Email: jose.nicolau@fm.hc.usp.br
Study Contact Backup
- Name: Juliana L L F Regueira, Postdoctoral Res. Associate
- Phone Number: 11959564983
- Email: julianaliraregueira@gmail.com
Study Locations
-
-
São Paulo
-
São Paulo, São Paulo, Brazil, 05403-900
- Recruiting
- Heart Institute, University of São Paulo Medical School (InCor/HCFMUSP)
-
Sub-Investigator:
- Juliana L. L. F. Regueira, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women aged ≥ 40 years.
- Willingness to sign the informed consent form.
- Absence of known atherosclerotic disease
Exclusion Criteria:
- Use of antiplatelet agents.
- Use of anticoagulants.
- Use of lipid-lowering agents.
- Use of oral hypoglycemic agents or insulin.
- Known atherosclerotic disease.
- Refusal to sign the informed consent form
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Control group
The same group of study participants.
Platelet aggregation tests without the addition of lipid nanoemulsions.
|
|
Case group
Study participants.
Platelet aggregation tests with the addition of lipid nanoemulsions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of Lipid Emulsions on Platelet Aggregation Assessed by Optical Aggregometry
Time Frame: Day 1 (single blood sample collection)
|
Comparison of the effect of different lipid emulsion formulations versus no emulsion (control) on platelet aggregation in blood samples from individuals without a history of ischemic disease.
|
Day 1 (single blood sample collection)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SDC: 6137/25/148
- 2023/10447-4 (Other Grant/Funding Number: Fapesp)
- 2025/29035-3 (Other Grant/Funding Number: Fapesp)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.